Reliability and validity of ultrasound to measure of muscle mass following allogeneic hematopoietic stem cell transplantation

Nao Hashida1, Yuma Tada2, Masayuki Suzuki3, Kumiko Ito4, Yuji Kato4, Hironari Tamiya3 & Jun Ishikawa2

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently show physical dysfunction due to loss of muscle mass. This study aimed to clarify the reliability and validity of ultrasound in evaluating muscle mass and to analyze the patterns of change in muscle mass before and after allo-HSCT. We conducted a prospective observational study using data from 68 patients who had undergone their first allo-HSCT. We evaluated the thickness of the quadriceps, biceps, and suprahyoid muscle. Three individual evaluators underwent this examination for each muscle before transplantation and on days 30, 90, and 180 after allo-HSCT. Inter-rater reliability was calculated using the interclass correlation (ICC), and the level of correlation between muscle mass measured by ultrasound and psoas muscle mass assessed using computed tomography (CT) was assessed using Pearson correlation. ICC values ranged from 0.897 to 0.977 in the measurement. The correlation scores were 0.730, 0.546 and 0.579 between psoas muscle and the biceps, quadriceps, and suprahyoid muscle. The thickness of the biceps and quadriceps muscle were both significantly decreased after allo-HSCT from baseline. These results showed that the ultrasound technique was a reliable tool for evaluating muscle mass and detecting changes in muscle mass following allo-HSCT.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapeutic treatment strategy for hematological malignancies. Conditioning regimens, including high-dose chemotherapy and total body irradiation, are necessary not only for the elimination of malignant hematopoietic cells but also for the engraftment of donor-derived hematopoietic stem cells. These highly cytotoxic conditioning regimens frequently result in severe stomatitis, gastrointestinal mucositis, and anorexia in allo-HSCT recipients1.

One of the major complications following allo-HSCT is graft-versus-host disease (GVHD), in which recipients mainly receive high-dose corticosteroid therapy, and consequently, they often get trapped in a state of hyper-catabolism. In allo-HSCT recipients, conditions such as stomatitis, mucositis, anorexia, and hyper-catabolism encompass malnutrition and physical dysfunction; that is, sarcopenia, mainly due to loss of muscle mass2–4. A previous report showed that 50.6% of patients receiving allo-HSCT had sarcopenia7. In addition, two studies showed that sarcopenia is a predictor of overall survival and non-relapse mortality5,6. Therefore, it is important to prevent sarcopenia from developing in patients as well as encourage them to maintain their physical function in order to prevent various complications and improve their QOL. However, examining physical function and muscle mass at an appropriate time is difficult because patients are occasionally isolated in a sterile room or are often in poor medical conditions after allo-HSCT8.

To date, the usefulness of ultrasound evaluation in evaluating muscle mass and age-related skeletal muscle atrophy in the upper and lower extremities or suprahyoid muscle has been reported in some studies9,10. There are a variety of methods for measuring muscle mass. Magnetic resonance imaging (MRI) and computed tomography (CT) are the gold standards for measuring skeletal muscle mass. Measurements of cross-sectional area or whole-body skeletal muscle mass can be precisely done with MRI or CT; however, they are expensive and
Bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA) have been widely and commonly used in the diagnosis of sarcopenia because of their ease of evaluation. However, muscle mass evaluated using BIA can be affected by the device as well as the patient's skin condition and edema. Because DXA does not directly estimate muscle mass, its measurements are estimated values. On the other hand, an ultrasound machine is portable and can directly measure muscle mass even if the allo-HSCT recipient is isolated in a sterile room or in poor condition. In this study, we examined the masses of three muscles: the quadriceps muscle, biceps muscle, and suprahyoid muscle. Evaluating quadriceps muscle thickness is particularly useful for the assessment of physical activity because of its important role in locomotor activity. The evaluation of the biceps muscle using ultrasound has also been reported as a significant indicator of sarcopenia and is directly associated with instrumental activities of daily living. Regarding the suprahyoid muscle, the styloglossus muscle has been reported not to be affected by sarcopenia. On the other hand, the geniohyoid muscle is not affected by respiratory input stimulation and has been reportedly associated with muscle mass loss with aging. In the previous study that evaluated the muscle mass of the masseter, geniohyoid, biceps and brachialis, and quadriceps femoris muscles to predict sarcopenia, the geniohyoid muscle mass was the best predictor.

The reliability and validity of ultrasound in assessing muscle mass in allo-HSCT recipients have not been fully understood. The aim of this study was to clarify the inter-rater reliability and validity of ultrasound for evaluating muscle mass and to analyze the patterns of change in muscle mass using ultrasound before and after allo-HSCT.

Methods

Study design and setting. We conducted a prospective observational study using data from recipients who had undergone their first allo-HSCT between April 2017 and March 2019 at our institute. Ninety-eight recipients underwent allo-HSCT, and 96 of them were enrolled with written informed consent. All recipients received physical therapy from physical therapists and nutrition care by a nutrition support team while they received myeloablative conditioning or reduced-intensity conditioning at the hospital. Physical therapy consisted of resistance training, aerobic exercise, and stretching. These programs started at least a week before the conditioning regimen for an inpatient setting (low-moderate intensity, 20–30 min sessions on weekdays). Recipients with poor physical function at the time of discharge were carefully monitored to assess their physical function. This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and approved by the ethics committee of the Osaka International Cancer Institute (approval number 1706089013-2).

Ultrasound examinations. Using Apio 300 (Canon Medical Systems Corporation, Tochigi, Japan), B-mode ultrasound imaging, three examiners evaluated the thickness of the quadriceps and biceps muscles, as well as the cross-sectional area of the suprahyoid muscles. A physician, a physical therapist, and a speech language therapist trained in ultrasound imaging performed the ultrasound imaging within a week before the transplantation and on days 30, 90, and 180 after allo-HSCT. We used a 7.5 MHz linear array probe to assess the thickness of the quadriceps and biceps muscles while a 6 MHz convex array probe was used to assess the cross-sectional area of the suprahyoid muscle. We measured the muscle mass on the right leg, arm, and middle of the floor of the mouth with the patient lying in a supine position and closing the mouth. (Fig. 1a; all images belong to N.H.) The landmarks for measurement were as follows: a 60% distal portion from the trochanter major to the epicondylus lateralis of the right thigh for the vastus intermedius muscle and rectus femoris muscle (c), and on the middle of the floor of the mouth for the geniohyoid-mylohyoid muscle complex (d). All images belong to N.H.
of the mouth for the cross-sectional area of the suprahyoid muscle (Fig. 1d). Since many previous studies used the cross-sectional area of the geniohyoid muscle to examine the relationship between sarcopenia and swallowing function, we measured cross-sectional area rather than thickness in this study. The vertical diameters of the vastus intermedius and rectus femoris muscle complex was measured on the inner edge of their respective muscles to evaluate the thickness of the quadriceps, and the vertical diameter of the biceps muscle was measured on the inner edge of the muscle (Fig. 2). We adjusted the angle of the probe to obtain optimal perpendicular imaging of the underlying bone for correct measurements of the vastus intermedius and rectus femoris muscle complex and biceps muscles. The geniohyoid-mylohyoid muscle complex was measured on the floor of the mouth in the central sagittal plane as the cross-sectional area of the suprahyoid muscle. We adjusted the position of the probe to view the hyoid bone, mandible, and geniohyoid muscle on a single screen.

Imaging of computed tomography. We measured the cross-sectional area of the psoas muscle using Aquilion PRIME (Canon Medical System Corporation, Tokyo, Japan) at 120 kV exposure. Manual tracing using CT imaging performed at the L3 level within a month before allo-HSCT was used to measure the cross-sectional areas of the bilateral psoas muscles.

Statistical analysis. Inter-rater reliability is the degree of agreement between two or more evaluators, which considers the coherence of the implementation of a scoring system. Inter-rater reliability was calculated using the interclass correlation (ICC), which is a method to determine agreement and is expressed as a relative measure of the explained variance of the total random variance. To estimate the validity of the ultrasound measurements, the level of correlation between pre-allo-HSCT ultrasound measurements and pre-allo-HSCT psoas muscle mass assessed using CT, which is known as the gold standard for evaluating muscle mass, was evaluated using Pearson correlation and a scatter plot. Each median value of the ultrasound examination data assessed by three evaluators was used for analysis. Repeated measures analysis of variance (ANOVA) followed by a paired t-test with Bonferroni adjustment was used to analyze the differences in muscle mass at different times. Post hoc univariate linear regression analysis was performed to identify variables that contributed to the rate of change from baseline in each muscle mass at day 90 after allo-HSCT.

Figure 2. Ultrasound images of the biceps muscle (a–d), the vastus intermedius muscle and rectus femoris muscle complex (e–h), and the geniohyoid-mylohyoid muscles complex (i–l) before and on days 30, 90 and 180 after allo-HSCT, respectively.
Ethical declarations. The present study was approved by the ethics committee of Osaka International Cancer Institute (approval number 1706089013-2), and general consent was obtained from all patients at the time of operation.

Results
Ninety-six patients were enrolled in this study. Among them, data from 68 recipients were available in the present study, of which 5 withdrew their consent and 17 dropped out due to relapse (n = 6), re-transportation (n = 2), and death (n = 9). The other six recipients were not able to undergo ultrasound evaluation at a certain point due to rejecting the evaluation due to physical and mental fatigue caused by GVHD or infection. The recipients’ characteristics are listed in Table 1. The mean age at allo-HSCT was 49 ± 12 years, and the diseases and donor sources were relatively well balanced. Acute GVHD was observed in 54 patients (79.4%). The mean length of hospital stay after allo-HSCT was 59.6 ± 23.9 days.

Inter-rater reliability. Table 2 shows the inter-rater reliability of the three evaluators for a total of 68 recipients, and thus, for a total of 273 evaluations. ICCs were 0.966, 0.977, 0.965, 0.964 in the biceps muscle; 0.962, 0.968, 0.975, 0.977 in the vastus intermedius muscle and rectus femoris muscle complex; and 0.899, 0.912, 0.897, 0.926 in the geniohyoid-mylohyoid muscle complex before and on days 30, 90 and 180 after allo-HSCT, respectively. All ICCs were high; thus, the measurements were reliable.

|                               | n = 68 |
|-------------------------------|--------|
| **Sex**                       |        |
| Female                        | 27 (39.7) |
| Male                          | 41 (60.3) |
| Age, y                        | 49.5 ± 12.4 |
| Body mass index               | 21.8 ± 2.8 |
| **Karnofsky performance status** |        |
| 100                           | 48 (70.6) |
| 90                            | 19 (27.9) |
| 80                            | 1 (1.5) |
| **Disease n, (%)**            |        |
| AML                           | 19 (27.9) |
| ALL/LBL                       | 16 (23.5) |
| ML                            | 17 (25.0) |
| MDS                           | 8 (11.8) |
| CML/MPN                       | 6 (8.8) |
| Other                         | 1 (1.5) |
| **Stem cell source, n (%)**   |        |
| HLA-matched or 1 mismatched rPB | 14 (20.6) |
| haploidentical rPB            | 15 (22.1) |
| uBM                           | 18 (26.5) |
| uPB                           | 2 (2.9) |
| CB                            | 19 (27.9) |
| **Conditioning regimens**     |        |
| MAC                           | 27 (39.7) |
| RIC                           | 41 (60.3) |
| **Period of neutrophil engraftment** | 15.68 ± 3.15 |
| **Acute GVHD**                |        |
| Non                           | 14 (20.6) |
| Grade I                       | 27 (39.7) |
| Grade II                      | 23 (33.8) |
| Grade III                     | 3 (4.4) |
| Grade IV                      | 1 (1.5) |

Table 1. Patients’ characteristics. AML, acute myeloid leukemia; ALL/LBL, acute lymphocytic leukemia/lymphoblastic lymphoma; ATLL, adult T-cell leukemia-lymphoma; ML, malignant lymphoma; MDS, myelodysplastic syndromes; CML/MPN, chronic myelogenous leukemia/myeloproliferative neoplasms, rPB: related peripheral blood, uBM: unrelated bone marrow, uPB: unrelated peripheral blood, CB: cord blood, MAC: myeloablative conditioning, RIC: reduced-intensity conditioning, GVHD: graft-versus-host disease.
Validity. Figure 3 shows the scatter plots illustrating the correlation between the cross-sectional area of the psoas muscle and thickness of the biceps muscle (a), the thickness of the quadriceps muscle (vastus intermedius muscle and rectus femoris muscle complex) (b), and the cross-sectional area of the suprahyoid muscle (geniohyoid-mylohyoid muscle complex) (c).

Changes in muscle mass. Figure 4 shows the change in the mean ± SD muscle thickness and cross-sectional area of the 68 recipients. The thickness of the biceps muscles significantly declined at days 90 and days 180 after allo-HSCT from baseline (18.6 ± 3.6 vs 16.7 ± 2.9, P < 0.001 and 16.9 ± 3.3, P < 0.001) and significantly declined at days 90 and days 180 after allo-HSCT from days 30 (17.9 ± 3.3 vs 16.7 ± 2.9, P < 0.001 and 16.9 ± 3.3, P < 0.001). The thickness of the vastus intermedius muscle and rectus femoris muscle complex also significantly declined at days 30, 90 and 180 after allo-HSCT from baseline (22.5 ± 5.6 vs 20.3 ± 4.9, P < 0.001, 19.1 ± 5.1, P < 0.001, and 18.9 ± 5.9, P < 0.001), and significantly declined at days 90 from days 30 (20.3 ± 4.9 vs 19.1 ± 5.1, P = 0.042). However, the difference was not statistically significant; the thickness of the biceps muscles slightly recovered at 180 days after allo-HSCT compared with that at days 90 after allo-HSCT. There were no significant changes in the cross-sectional area of the geniohyoid-mylohyoid muscle complex. Supplementary Table S2 shows the post hoc univariate linear regression analysis. Steroid use was significantly associated with the rate of change in the biceps, vastus intermedius, and rectus femoris muscle complex thicknesses.

### Table 2. Inter rater reliability of measurement of muscle mass using ultrasound. allo-HSCT: allogeneic hematopoietic stem cell transplantation. CSA: cross sectional area.

|                                | ICC (95% CI)          |
|--------------------------------|-----------------------|
| **Biceps muscle thickness**    |                       |
| Before allo-HSCT               | 0.966 (0.953–0.976)   |
| Days 30 after allo-HSCT        | 0.977 (0.968–0.984)   |
| Days 90 after allo-HSCT        | 0.965 (0.950–0.976)   |
| Days 180 after allo-HSCT       | 0.964 (0.947–0.975)   |
| **Vastus intermedius muscle and rectus femoris muscle complex thickness** |                       |
| Before allo-HSCT               | 0.962 (0.948–0.973)   |
| Days 30 after allo-HSCT        | 0.968 (0.955–0.977)   |
| Days 90 after allo-HSCT        | 0.975 (0.964–0.983)   |
| Days 180 after allo-HSCT       | 0.977 (0.966–0.984)   |
| **CSA of geniohyoid-mylohyoid muscle complex** |                       |
| Before allo-HSCT               | 0.899 (0.863–0.927)   |
| Days 30 after allo-HSCT        | 0.912 (0.879–0.937)   |
| Days 90 after allo-HSCT        | 0.897 (0.856–0.929)   |
| Days 180 after allo-HSCT       | 0.926 (0.895–0.950)   |

**Figure 3.** Scatter plots illustrating correlations between cross-sectional area of the psoas muscle and thickness of the biceps muscle (a), thickness of the quadriceps muscle (vastus intermedius muscle and rectus femoris muscle complex) (b), and cross-sectional area of the suprahyoid muscle (geniohyoid-mylohyoid muscle complex) (c).
Discussion
Our results suggest that ultrasonography is a valid and reliable method for assessing muscle mass in allo-HSCT recipients. In addition, this study also showed that ultrasound was able to detect changes in muscle mass, including the quadriceps and biceps muscles, in allo-HSCT recipients.

In this study, the measurements of muscle mass by ultrasound were highly reliable, with ICCs between 89.7% and 97.7%. Although muscle atrophy and edema occasionally occurred in allo-HSCT recipients, we obtained reliable results that were nearly equal to those of other studies\(^11^,\^12^,\^23\).

The validity of the ultrasound measurements was determined according to their correlation with psoas muscle mass as measured by CT. To assess whole-body muscle and sarcopenia, measurement of psoas muscle mass using CT is widely used as a gold standard\(^24\). Our findings revealed that psoas muscle mass measured by CT was highly correlated with the thickness of the biceps, vastus intermedius, and rectus femoris muscle complex, as well as the cross-sectional area of the geniohyoid-mylohyoid muscle complex, all measured by ultrasound. These results suggest that ultrasonography is a valid modality for assessing muscle mass and sarcopenia. In a meta-analysis of retrospective cohort studies, sarcopenia was found to be associated with non-relapse mortality and overall survival in patients after hematopoietic stem cell transplantation\(^25\). Thus, it is important for allo-HSCT recipients to assess muscle mass. Of these three muscles, we found that the thickness of the biceps muscle as measured by ultrasound was most correlated with the mass of the psoas muscle as measured by CT. This finding suggested that the biceps muscle might be more suitable for assessing muscle thickness using ultrasound.

In this study, we were able to detect changes in the thickness of the biceps and quadriceps muscles after allo-HSCT. All muscle masses decreased until day 90 after allo-HSCT. Some studies have reported that muscle mass decreases after allo-HSCT and autologous stem cell transplantation\(^2,\^26,\^27\). These studies showed a decrease in fat-free mass and muscle mass assessed between 17 and 100 days after transplantation. In this study, the thickness of the vastus intermedius muscle and rectus femoris muscle complex declined more sharply than the biceps muscle on days 30 after allo-HSCT, while the thickness of the biceps muscle declined more sharply from days 30 to 90 than the vastus intermedius muscle and rectus femoris muscle complex after allo-HSCT. In general, it has been reported that disuse or steroid-induced muscle atrophy occurs more frequently in lower limb muscles than in upper limb muscles\(^12,\^28\). Our results were different from those of previous studies\(^29\). After allo-HSCT, patients received physical therapy to strengthen their lower limb muscles; consequently, the mass of the lower limb muscle might recover more rapidly than that of the upper limb muscle. There were no significant changes in the cross-sectional area of the geniohyoid-mylohyoid muscle complex after allo-HSCT. Based on the findings that changes in the cross-sectional area of the geniohyoid-mylohyoid muscle complex were smaller than the changes in other muscles, the suprahyoid muscles might be less affected by disease, malnutrition, or steroid myopathy compared to other muscles.

All muscle masses evaluated tended to recover or stop declining from day 90 to 180 after allo-HSCT. Physical activity has been reported to increase at 3 and 6 months after allo-HSCT, with exercise programs having an effect on muscle strength and aerobic capacity\(^6\). Moreover, most recipients who received allo-HSCT exhibited...
malnutrition at the time of discharge, but the number of recipients was decreased upon long-term follow-up\textsuperscript{20,31}. Therefore, three months after allo-HSCT, the recipients’ activities and nutritional intake may be essential for improving muscle mass atrophy.

At the 180 days follow-up, we obtained data of 69% (68 patients) in this study. These results are higher than those of a previous study that evaluated 40.7% of recipients who met the inclusion criteria for physical assessment and muscle mass on BIA\textsuperscript{2}. Evaluating physical function is sometimes difficult for allo-HSCT recipients due to medical problems or fatigue. In addition, assessing muscle mass with CT or BIA is also difficult due to the patient being in an isolation room or having edema\textsuperscript{2}. Thus, obtaining a high rate of follow-up data in this study suggested that ultrasound measurement could be a good alternative method for evaluating muscle mass.

In conclusion, we found that ultrasound measurement of muscle mass is a reliable and valid tool for allo-HSCT recipients and may be useful particularly when we were not able to assess physical ability. In addition, the results of changes in muscle mass suggested that muscle mass tended to decrease after allo-HSCT but started to recover from day 90 after allo-HSCT. Further studies are needed to clarify the association between ultrasound measurements and physical ability.

Received: 23 June 2021; Accepted: 14 January 2022
Published online: 27 January 2022

References
1. Baumgartner, A. et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation—A systematic review. Bone Marrow Transplant. 52, 506–513. https://doi.org/10.1038/bmt.2016.310 (2017).
2. Takekiyo, T. et al. Effect of exercise therapy on muscle mass and physical ability in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer 23, 985–992. https://doi.org/10.1007/s00520-014-2425-7 (2015).
3. Baumann, F. T. et al. Absence of morphological and molecular correlates of sarcopenia in the macaque tongue muscle styloglossus. Eur. J. Phys. Rehabil. Med. 86, 2947–2953. https://doi.org/10.1037/0033-295X.111.4.1061 (2004).
4. Urbain, P. et al. Multidimensional follow-up of nutritional status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 48, 446–451. https://doi.org/10.1038/bmt.2012.158 (2013).
5. Hamada, R. et al. Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation. Support Care Cancer https://doi.org/10.1007/s00520-019-05124-1 (2019).
6. Jarden, M., Baadsgaard, M. T., Hovgaard, D. J., Boesen, E. & Adamsen, L. A randomized trial on the effect of a multimodal intervention on physical and functional performance in adult patients undergoing allogeneic SCT. Bone Marrow Transplant 43, 725–737. https://doi.org/10.1038/bmt.2009.27 (2009).
7. Mortishita, S. et al. Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation. Support Care Cancer 20, 3161–3168. https://doi.org/10.1007/s00520-012-1460-5 (2012).
8. Ando, T. et al. Computed tomography-defined sarcopenia: Prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study. Int. J. Hematol. 112, 46–56. https://doi.org/10.1007/s12185-020-02870-5 (2020).
9. Sakatoku, K. et al. Prognostic significance of low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing hematopoietic stem cell transplantation. Int. J. Hematol. 111, 267–277. https://doi.org/10.1185/10185-019-02773-0 (2020).
10. Skaarud, K. J. et al. Body weight, body composition and survival after 1 year: Follow-up of a nutritional intervention trial in allo-HSCT recipients. Bone Marrow Transplant. 54, 2102–2109. https://doi.org/10.1038/s41409-019-0638-6 (2019).
11. Nijholt, W., Scafgioli, A., Jager-Wittenaar, H., Hobbelen, J. S. M. & van der Schans, C. P. The reliability and validity of ultrasound to quantify muscles in older adults: A systematic review. J. Cachexia Sarcopenia Muscle 8, 702–712. https://doi.org/10.1007/jcsm.12210 (2017).
12. Hernandez-Socorro, C. R., Saavedra, P., Lopez-Fernandez, J. C. & Ruiz-Santana, S. Assessment of muscle wasting in long-stay ICU patients using a new ultrasound protocol. Nutrients 10, 1849. https://doi.org/10.3390/nu10111849 (2018).
13. Morat, T., Gilmore, K. J. & Rice, C. L. Neuromuscular function in different stages of sarcopenia. Exp. Gerontol. 81, 28–36. https://doi.org/10.1016/j.exger.2016.04.014 (2016).
14. Evans, W. J., Hellerstein, M., Orwoll, E., Cummings, S. & Cawthon, P. M. D(3)-creatine dilution and the importance of accuracy in the assessment of skeletal muscle mass. J. Cachexia Sarcopenia Muscle 10, 14–21. https://doi.org/10.1007/jcsm.12390 (2019).
15. Parry, S. M. et al. Ultrasoundography in the intensive care setting can be used to detect changes in the quality and quantity of muscle and is related to muscle strength and function. J. Crit. Care 30, 1151.e1159–1114. https://doi.org/10.1016/j.jcrc.2015.05.024 (2015).
16. Li, S. et al. Ultrasound for measuring the cross-sectional area of biceps brachii muscle in sarcopenia. J. Int. Med. Sci. 17, 2947–2953. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC694657 (2020).
17. Sokoloff, A. J. et al. Absence of morphological and molecular correlates of sarcopenia in the macaque tongue muscle styloglossus. Exp. Gerontol. 84, 40–48. https://doi.org/10.1016/j.exger.2016.010.016 (2016).
18. Feng, X. et al. Ultrasonographic evaluation of geniohyoid muscle and hyoid bone during swallowing in young adults. Laryngoscope 125, 1886–1891. https://doi.org/10.1002/lary.25224 (2015).
19. Barotsi, N., Galata, A., Hadjiconstanti, A. & Panayiotakis, G. The ultrasonographic measurement of muscle thickness in sarcopenia: A prediction study. Eur. J. Phys. Rehabil. Med. 56, 427–437. https://doi.org/10.23736/s1913-9087.2006222-x (2020).
20. Chen, K. C. et al. Sarcopenic dysphagia: A narrative review from diagnosis to intervention. Nutrients 13, 4043. https://doi.org/10.3390/nu131114043 (2021).
21. Shroot, P. E. & Fleiss, J. L. Intraclass correlations: Uses in assessing rater reliability. Psychol. Bull. 86, 420–428. https://doi.org/10.1037/0033-2909.86.2.420 (1979).
22. Borsboom, D., Mellenbergh, G. J. & van Heerden, J. The concept of validity. Psychol. Rev. 111, 1061–1071. https://doi.org/10.1037/0033-295X.111.4.1061 (2004).
23. Mul, K. et al. Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: Complementary imaging biomarkers. J. Neurol. 265, 2646–2655. https://doi.org/10.1007/s00415-018-9357-y (2018).
24. Cruz-Jentoft, A. J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 48, 16–31. https://doi.org/10.1093/ageing/aay169 (2019).
25. Ija, S. et al. Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: A systematic review and meta-analysis. Support Care Cancer 28, 3533–3542. https://doi.org/10.1007/s00520-020-05359-3 (2020).
Author contributions
N.H., Y.T., K.I., and Y.K. were involved in study design. N.H., Y.T., M.S., K.I., and Y.K performed data analysis and data interpretation. N.H drafted the work. N.H., Y.T., M.S., K.I., Y.K., H.T. and J.I. revised it critically for important intellectual content. N.H., Y.T., M.S., K.I., Y.K., H.T. and J.I. approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-05577-1.

Correspondence and requests for materials should be addressed to N.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022